Street Calls of the Week
Maze Therapeutics, Inc. (NASDAQ:MAZE), a biotechnology company with a market capitalization of $635.4 million, announced Tuesday that its board of directors has appointed Misbah Tahir as chief financial officer and principal financial officer, effective the same day. The information is based on a press release statement filed with the Securities and Exchange Commission. According to InvestingPro data, the company maintains a strong liquidity position with more cash than debt on its balance sheet, though it faces challenges as it rapidly depletes its cash reserves.
According to the filing, before joining Maze Therapeutics , Mr. Tahir served as chief financial officer of IGM Biosciences, Inc. from January 2019 to August 2025. He previously held the role of vice president of finance at Dermira, Inc. from January 2014 to December 2018, and held finance leadership positions at Onyx Pharmaceuticals, Inc. and Human Genome Sciences Inc. Mr. Tahir began his career at Amgen, Inc. after working as a management consultant at Oliver Wyman. He holds a B.A. in International Relations from the University of Pennsylvania and an M.B.A. from the University of Michigan Business School.
The company’s compensation committee approved an offer letter for Mr. Tahir that includes an initial annual base salary of $500,000, an annual discretionary bonus opportunity of up to 40% of his base salary, and a one-time sign-on bonus of $50,000, which is subject to repayment if his service is less than one year. Mr. Tahir will also receive an option to purchase up to 325,000 shares of Maze Therapeutics common stock, with vesting terms outlined in the agreement.
Mr. Tahir will participate in the company’s Amended and Restated Executive Severance and Change in Control Plan. If terminated without cause outside of a change in control, he is eligible for a lump sum severance payment equal to nine months of base salary and continued medical benefits for up to nine months. In the event of termination without cause or for good reason within a specified period surrounding a change in control, Mr. Tahir is entitled to a lump sum equal to his annual base salary and target bonus, continued COBRA coverage for up to 12 months, and accelerated vesting of outstanding equity awards, subject to certain conditions.
Maze Therapeutics stated there are no arrangements or understandings with other persons regarding Mr. Tahir’s appointment, and no family relationships exist between Mr. Tahir and any company directors or executive officers.
In other recent news, H.C. Wainwright has initiated coverage on Maze Therapeutics with a Buy rating. The firm set a price target of $34.00, indicating confidence in the company’s potential, particularly highlighting its kidney disease treatment. Maze Therapeutics is developing MZE782, a first-in-class SLC6A19 small molecule inhibitor aimed at treating chronic kidney disease. The research firm described this treatment as a potential "game changer" for the company. Phase 1 proof-of-concept data for MZE782 is anticipated to be released in the third quarter of 2025. These developments reflect the company’s ongoing efforts to advance its pipeline and address significant medical needs. The analyst’s positive outlook is based on the potential impact of this treatment on the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.